Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study

G. Raghu, MJ. Hamblin, AW. Brown, JA. Golden, LA. Ho, MS. Wijsenbeek, M. Vasakova, A. Pesci, DE. Antin-Ozerkis, KC. Meyer, M. Kreuter, T. Burgess, N. Kamath, F. Donaldson, L. Richeldi

. 2022 ; 23 (1) : 129. [pub] 20220521

Language English Country Great Britain

Document type Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc22018349

BACKGROUND: Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-202 study. Interim (76-week) data from the open-label extension (OLE) demonstrated sustained safety and efficacy with rhPTX-2 treatment. Here, we present the entire long-term OLE safety and efficacy data to 128 weeks. METHODS: Patients who completed the randomized PRM-151-202 study period were eligible for the OLE, during which all patients received rhPTX-2, having started rhPTX-2 (i.e., crossed from placebo) or continued rhPTX-2 after Week 28. rhPTX-2 was administered in 28-week cycles, with 10 mg/kg intravenous infusions (60 min) on Days 1, 3, and 5 in the first week of each cycle, then one infusion every 4 weeks up to Week 128. The OLE primary objective was to assess the long-term safety and tolerability of rhPTX-2. Other outcomes included FVC, 6MWD, and patient-reported outcomes (descriptive analysis). RESULTS: All 111 patients who completed the randomized period entered the OLE (n = 37 started rhPTX-2; n = 74 continued rhPTX-2); 57 (51.4%) completed to Week 128. The treatment-emergent adverse event (TEAE) profile was consistent with the randomized period, with the majority of TEAEs graded mild or moderate. Serious TEAEs occurred in 47 patients (42.3%), most frequently IPF (n = 11; 9.9%), pneumonia (n = 7; 6.3%), and acute respiratory failure (n = 3; 2.7%). Three patients underwent lung transplantation. Most serious TEAEs (and all 14 fatal events) were considered unrelated to rhPTX-2 treatment. For patients starting vs continuing rhPTX-2, mean (95% confidence interval) changes from baseline to Week 128 were, respectively, - 6.2% (- 7.7; - 4.6) and - 5.7% (- 8.0; - 3.3) for percent predicted FVC and - 36.3 m (- 65.8; - 6.9) and - 28.9 m (- 54.3; - 3.6) for 6MWD; however, conclusions were limited by patient numbers at Week 128. CONCLUSIONS: Long-term treatment (up to 128 weeks) with rhPTX-2 was well tolerated in patients with IPF, with no new safety signals emerging in the OLE. The limited efficacy data over 128 weeks may suggest a trend towards a treatment effect. Trial registration NCT02550873; EudraCT 2014-004782-24.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018349
003      
CZ-PrNML
005      
20220804134722.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12931-022-02047-0 $2 doi
035    __
$a (PubMed)35597980
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Raghu, Ganesh $u Center for Interstitial Lung Diseases, Department of Medicine and Laboratory Medicine, University of Washington, Seattle, WA, USA. graghu@uw.edu $1 https://orcid.org/0000000175066643
245    10
$a Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study / $c G. Raghu, MJ. Hamblin, AW. Brown, JA. Golden, LA. Ho, MS. Wijsenbeek, M. Vasakova, A. Pesci, DE. Antin-Ozerkis, KC. Meyer, M. Kreuter, T. Burgess, N. Kamath, F. Donaldson, L. Richeldi
520    9_
$a BACKGROUND: Recombinant human pentraxin-2 (rhPTX-2) significantly decreased decline in percent predicted forced vital capacity (FVC) and stabilized 6-min walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF) during the 28-week, placebo-controlled, randomized period of the Phase II PRM-151-202 study. Interim (76-week) data from the open-label extension (OLE) demonstrated sustained safety and efficacy with rhPTX-2 treatment. Here, we present the entire long-term OLE safety and efficacy data to 128 weeks. METHODS: Patients who completed the randomized PRM-151-202 study period were eligible for the OLE, during which all patients received rhPTX-2, having started rhPTX-2 (i.e., crossed from placebo) or continued rhPTX-2 after Week 28. rhPTX-2 was administered in 28-week cycles, with 10 mg/kg intravenous infusions (60 min) on Days 1, 3, and 5 in the first week of each cycle, then one infusion every 4 weeks up to Week 128. The OLE primary objective was to assess the long-term safety and tolerability of rhPTX-2. Other outcomes included FVC, 6MWD, and patient-reported outcomes (descriptive analysis). RESULTS: All 111 patients who completed the randomized period entered the OLE (n = 37 started rhPTX-2; n = 74 continued rhPTX-2); 57 (51.4%) completed to Week 128. The treatment-emergent adverse event (TEAE) profile was consistent with the randomized period, with the majority of TEAEs graded mild or moderate. Serious TEAEs occurred in 47 patients (42.3%), most frequently IPF (n = 11; 9.9%), pneumonia (n = 7; 6.3%), and acute respiratory failure (n = 3; 2.7%). Three patients underwent lung transplantation. Most serious TEAEs (and all 14 fatal events) were considered unrelated to rhPTX-2 treatment. For patients starting vs continuing rhPTX-2, mean (95% confidence interval) changes from baseline to Week 128 were, respectively, - 6.2% (- 7.7; - 4.6) and - 5.7% (- 8.0; - 3.3) for percent predicted FVC and - 36.3 m (- 65.8; - 6.9) and - 28.9 m (- 54.3; - 3.6) for 6MWD; however, conclusions were limited by patient numbers at Week 128. CONCLUSIONS: Long-term treatment (up to 128 weeks) with rhPTX-2 was well tolerated in patients with IPF, with no new safety signals emerging in the OLE. The limited efficacy data over 128 weeks may suggest a trend towards a treatment effect. Trial registration NCT02550873; EudraCT 2014-004782-24.
650    _2
$a lidé $7 D006801
650    12
$a idiopatická plicní fibróza $x farmakoterapie $7 D054990
650    12
$a rekombinantní proteiny $x škodlivé účinky $7 D011994
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vitální kapacita $7 D014797
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Hamblin, Mark J $u Pulmonary and Critical Care Medicine, University of Kansas Medical Center, Kansas City, KS, USA
700    1_
$a Brown, A Whitney $u Inova Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA
700    1_
$a Golden, Jeffrey A $u Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
700    1_
$a Ho, Lawrence A $u Center for Interstitial Lung Diseases, Department of Medicine and Laboratory Medicine, University of Washington, Seattle, WA, USA
700    1_
$a Wijsenbeek, Marlies S $u Department of Respiratory Medicine, Erasmus MC, University Medical Center, Rotterdam, Netherlands
700    1_
$a Vasakova, Martina $u Department of Respiratory Medicine, First Faculty of Medicine of Charles University and Thomayer Hospital, Prague, Czech Republic
700    1_
$a Pesci, Alberto $u School of Medicine and Surgery, University of Milano-Bicocca, ASST-Monza, Milano, Italy
700    1_
$a Antin-Ozerkis, Danielle E $u Pulmonary, Critical Care, and Sleep Medicine, Yale School of Medicine, New Haven, CT, USA
700    1_
$a Meyer, Keith C $u Department of Medicine, Division of Pulmonary and Critical Care, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
700    1_
$a Kreuter, Michael $u Center for Interstitial and Rare Lung Diseases, Department of Pneumology, Thoraxklinik, University of Heidelberg and German Center for Lung Research, Heidelberg, Germany
700    1_
$a Burgess, Tracy $u Genentech, Inc., South San Francisco, CA, USA
700    1_
$a Kamath, Nikhil $u Roche Products Ltd., Welwyn Garden City, UK
700    1_
$a Donaldson, Francis $u Roche Products Ltd., Welwyn Garden City, UK
700    1_
$a Richeldi, Luca $u Fondazione Policlinico Universitario A Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
773    0_
$w MED00006600 $t Respiratory research $x 1465-993X $g Roč. 23, č. 1 (2022), s. 129
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35597980 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134716 $b ABA008
999    __
$a ok $b bmc $g 1822106 $s 1169592
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 23 $c 1 $d 129 $e 20220521 $i 1465-993X $m Respiratory research $n Respir Res $x MED00006600
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options